U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C47H51NO14
Molecular Weight 853.9061
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PACLITAXEL

SMILES

CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C6=CC=CC=C6)C7=CC=CC=C7

InChI

InChIKey=RCINICONZNJXQF-MZXODVADSA-N
InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

HIDE SMILES / InChI

Molecular Formula C47H51NO14
Molecular Weight 853.9061
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 11 / 11
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. Taxol is marketed for the treatment of Breast cancer; Gastric cancer; Kaposi's sarcoma; Non-small cell lung cancer; Ovarian cancer. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. Paclitaxel is a taxoid antineoplastic agent indicated as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast cancer. Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer. Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer.
2000 Dec
A paclitaxel-containing chemotherapy does not cause central nervous adverse effects: a prospective study in patients with ovarian cancer.
2000 Sep-Oct
Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations.
2001
The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
2001
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
2001
High affinity binding of paclitaxel to human serum albumin.
2001 Apr
Management of recurrent juvenile granulosa cell tumor of the ovary.
2001 Apr
Recurrent metastatic fallopian tube carcinoma in pregnancy.
2001 Apr
HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?
2001 Apr
Cell cycle-related changes in regulatory volume decrease and volume-sensitive chloride conductance in mouse fibroblasts.
2001 Apr
Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells.
2001 Apr 1
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300.
2001 Apr 13
Regional drug delivery with radiation for the treatment of Ewing's sarcoma. In vitro development of a taxol release system.
2001 Apr 2
Taxol-induced cell cycle arrest and apoptosis: dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition.
2001 Apr 26
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
2001 Feb
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
2001 Feb
Gemcitabine plus cisplatin in breast cancer.
2001 Feb
Phytochemistry and medicinal plants.
2001 Feb
Membrane macrophage colony-stimulating factor on MADB106 breast cancer cells does not activate cytotoxic macrophages but immunizes rats against breast cancer.
2001 Feb
Isolation of cortical MTs from tobacco BY-2 cells.
2001 Feb
Selective drug resistant human osteosarcoma cell lines.
2001 Feb
Changes in glycosylation during Drosophila development. The influence of ecdysone on hemomucin isoforms.
2001 Feb
Disruption of microtubular cytoskeleton induced by cryptogein, an elicitor of hypersensitive response in tobacco cells.
2001 Feb
Involvement of Asp-Glu-Val-Asp-directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells.
2001 Feb
Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
2001 Feb 9
Phase I study of paclitaxel (Taxol) plus vinorelbine (Navelbine) in patients with untreated stage IIIb and IV non-small cell lung cancer.
2001 Feb-Mar
Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine.
2001 Feb-Mar
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
2001 Jan
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
2001 Jan
Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.
2001 Jan
Colchicine and griseofulvin inhibit VCAM-1 expression on human vascular endothelial cells - evidence for the association of VCAM-1 expression with microtubules.
2001 Jan
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
2001 Jan 15
Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
2001 Jan 15
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
2001 Jan 15
Stimulation of taxol production and excretion in Taxus spp cell cultures by rare earth chemical lanthanum.
2001 Jan 23
Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner.
2001 Jan 4
Enhanced taxol production and release in Taxus chinensis cell suspension cultures with selected organic solvents and sucrose feeding.
2001 Jan-Feb
The role of actin filaments and microtubules in hepatocyte spheroid self-assembly.
2001 Mar
Dynamic events are differently mediated by microfilaments, microtubules, and mitogen-activated protein kinase during porcine oocyte maturation and fertilization in vitro.
2001 Mar
Effects of stathmin inhibition on the mitotic spindle.
2001 Mar
Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study.
2001 Mar 1
Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3.
2001 Mar 1
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
2001 Mar 1
Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.
2001 Mar 12
Paclitaxel restores radiation-induced apoptosis in a bcl-2-expressing, radiation-resistant lymphoma cell line.
2001 Mar 15
Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol.
2001 Mar-Apr
Inhibition of telomerase activity as a measure of tumor cell killing by cisplatin in squamous cell carcinoma cell line.
2001 Mar-Apr
P-glycoprotein efflux pump expression and activity in Calu-3 cells.
2001 May
Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2.
2001 May 11
Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines.
2001 May-Jun
Patents

Sample Use Guides

In Vivo Use Guide
For previously untreated patients with carcinoma of the ovary, one of the following recommended regimens may be given every 3 weeks. a.TAXOL (PACLITAXEL) administered intravenously over 3 hours at a dose of 175 mg/m2 followed by cisplatin at a dose of 75 mg/m2; or b.TAXOL (PACLITAXEL) administered intravenously over 24 hours at a dose of 135 mg/m2 followed by cisplatin at a dose of 75 mg/m2 2) In patients previously treated with chemotherapy for carcinoma of the ovary, the recommended regimen is TAXOL (PACLITAXEL) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks.
Route of Administration: Intravenous
In Vitro Use Guide
Paclitaxel inhibited tubulin polymerization in the presence of MAPs in vitro with an IC50 value of 38.19 ± 3.33 uM in living cancer cells (Hela cells and human osteosarcoma U2OS cells).
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:43:31 UTC 2019
Edited
by admin
on Mon Oct 21 20:43:31 UTC 2019
Record UNII
P88XT4IS4D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PACLITAXEL
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ONCOGEL
Common Name English
PACLITAXEL [MART.]
Common Name English
BMS 181339-01
Code English
EBETAXEL
Common Name English
PAXENE
Brand Name English
NSC-125973
Code English
INTAXEL
Common Name English
TAXOL
Brand Name English
PACLITAXEL [USAN]
Common Name English
MITOTAX
Common Name English
ABI-007
Code English
PACLITAXEL [USP-RS]
Common Name English
PACLITAXEL PROTEIN-BOUND
Common Name English
BMS-181339-01
Code English
NAB-PACLITAXEL COMPONENT PACLITAXEL
Common Name English
ONXAL
Common Name English
GENETAXYL
Common Name English
PACLITAXEL [EP]
Common Name English
MBT 0206
Code English
NK 105
Code English
PACLITAXEL [ORANGE BOOK]
Common Name English
DHP 107
Code English
PACLITAXEL [USP]
Common Name English
CAPXOL
Common Name English
PACLITAXEL [MI]
Common Name English
PACLITAXEL [VANDF]
Common Name English
GENEXOL
Brand Name English
PACLITAXEL [GREEN BOOK]
Common Name English
EMPAC
Common Name English
PLAXICEL
Common Name English
GENEXOL-PM
Common Name English
ABI 007
Common Name English
TAXUS
Common Name English
PACLIEX
Common Name English
ENDOTAG 1
Common Name English
(-)-PACLITAXEL
Common Name English
LIPOSOME-ENTRAPPED PACLITAXEL EASY-TO-USE
Common Name English
TAXOL A
Common Name English
PACLITAXEL (TAXUS CANADENSIS)
Common Name English
ABRAXANE COMPONENT PACLITAXEL
Brand Name English
PACLITAXEL [EMA EPAR]
Common Name English
PACLITAXEL [INN]
Common Name English
GENAXOL
Common Name English
PACLITAXEL [JAN]
Common Name English
TAXALBIN
Common Name English
YEWTAXAN
Brand Name English
PACLITAXEL [WHO-DD]
Common Name English
CYCLOPAX
Common Name English
PACLITAXOL
Common Name English
LEP-ETU
Common Name English
TAXUS STENT
Common Name English
ZISU
Brand Name English
TOCOSOL PACLITAXEL
Common Name English
QW-8184
Code English
PACLITAXEL [HSDB]
Common Name English
ONXOL
Brand Name English
TAXUS LIBERTE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 270208
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 50190
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
NDF-RT N0000175085
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
LIVERTOX 730
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 394813
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
NCI_THESAURUS C67437
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
EU-Orphan Drug EU/3/06/422
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 454014
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
WHO-VATC QL01CD01
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 594217
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 469915
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 103497
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 186404
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 482015
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
NDF-RT N0000175592
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 278309
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 384912
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 104797
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 454114
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
EMA ASSESSMENT REPORTS PAXENE (WITHDRAWN: OVARIAN NEOPLASMS)
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
CFR 21 CFR 516.1684
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 290709
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 252907
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
NCI_THESAURUS C1490
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
WHO-ATC L01CD01
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
EMA ASSESSMENT REPORTS ABRAXANE (AUTHORIZED: PANCREATIC NEOPLASMS)
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 291009
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
EMA ASSESSMENT REPORTS PAXENE (WITHDRAWN: CARCINOMA, NON-SMALL-CELL LUNG)
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 141701
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
FDA ORPHAN DRUG 280409
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
Code System Code Type Description
CAS
33069-62-4
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
MESH
D017239
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
HSDB
33069-62-4
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
ChEMBL
CHEMBL428647
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
EPA CompTox
33069-62-4
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
DRUG BANK
DB01229
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
IUPHAR
2770
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
INN
7052
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
WIKIPEDIA
PACLITAXEL
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
RXCUI
56946
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
LactMed
33069-62-4
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
EVMPD
SUB09583MIG
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
NCI_THESAURUS
C1411
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
PUBCHEM
36314
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
MERCK INDEX
M8351
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY Merck Index
MESH
C495179
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
PRIMARY
RXCUI
486610
Created by admin on Mon Oct 21 20:43:31 UTC 2019 , Edited by admin on Mon Oct 21 20:43:31 UTC 2019
ALTERNATIVE
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INDUCER
Paclitaxel activates pregnane X receptor (PXR)
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
Paclitaxel activates pregnane X receptor (PXR)
TRANSPORTER -> SUBSTRATE
BINDER->LIGAND
BINDING
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
METABOLITE -> PARENT
In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6α-hydroxypaclitaxel by CYP2C8; and to two minor metabolites, 3'-p-hydroxypaclitaxel and 6α, 3'-p-dihydroxypaclitaxel, by CYP3A4.
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC